Who
-
Study population: Close contacts aged ≥2 years of laboratory-confirmed pulmonary TB patients in Singapore.
-
Sample size: 60,377 unique contacts (62,724 observations) linked to 7,737 index TB cases.
-
Key characteristics: Majority male, predominantly Chinese ethnicity, mostly Singapore residents; 75% of contacts were aged >25 years.
-
Outcome group: 150 contacts (0.3%) who developed active TB disease despite being IGRA-negative.
What
-
Focus: Identification of risk factors for developing active TB disease among IGRA-negative close contacts.
-
Key findings: Independent risk factors included:
-
Age >25 years
-
Malay ethnicity
-
Diabetes mellitus
-
End-stage renal failure
-
Exposure to smear-positive index cases
-
Family relationship with the index case
-
Exposure in dormitories or nursing homes
-
-
Implications: IGRA-negative contacts with these risk factors have a substantially higher TB incidence than the general population, suggesting possible false-negative IGRA results and need for enhanced follow-up.
When
-
Study period: January 2014 to December 2022.
-
Follow-up: Median time to TB disease development was 92 weeks after index case notification.
Where
-
Setting: Singapore.
-
Program context: National Tuberculosis Programme (NTBP), using data from the national TB registry.
Why
-
To inform context-specific follow-up strategies for IGRA-negative close contacts, addressing uncertainty about residual TB risk after a negative IGRA result and supporting Singapore’s goal of reducing TB incidence to 10 per 100,000 by 2040.
How
-
Design: Retrospective cohort study.
-
Inclusion criteria: Close contacts with a negative QuantiFERON-TB Gold Plus (QFT-Plus) result at 8 weeks post-exposure.
-
Exclusions: Prior TB treatment or preventive therapy; screening with TB-SPOT only.
-
Analysis:
-
Univariate analyses (chi-square, Fisher’s exact, Mann–Whitney U tests).
-
Multivariable logistic regression including variables with P <0.1 or strong prior evidence.
-
Model performance assessed using ROC curve (AUC = 0.79).
-
-
Conclusion: Authors recommend reviewing IGRA retesting timing and extending follow-up to 24 months for high-risk IGRA-negative contacts.
No comments:
Post a Comment